Breaking News Instant updates and real-time market news.

WEN

Wendy's

$12.94

-0.05 (-0.38%)

, SAIC

SAIC

$83.40

-0.56 (-0.67%)

10:36
11/29/16
11/29
10:36
11/29/16
10:36

On The Fly: Top five analyst downgrades

On The Fly: Top five analyst downgrades: 1. Wendy's (WEN) downgraded to Neutral from Buy at Goldman with analyst Karen Holthouse citing valuation with the stock up 23% over the past month. 2. SAIC (SAIC) downgraded to Neutral from Buy at Citi with analyst Jonathan Raviv citing the recent rally in the shares and some overhang from the pending contract transition. 3. BioMarin (BMRN), Johnson & Johnson (JNJ), and Vertex (VRTX) were downgraded to Equal Weight from Overweight at Barclays. 4. Nivalis Therapeutics (NVLS) downgraded to Market Perform Raymond James, to Hold from Buy at Stifel, to Market Perform from Outperform at Cowen, and to Neutral from Outperform at Baird. 5. U.S. Steel (X) downgraded to Hold from Buy at Argus. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.

WEN

Wendy's

$12.94

-0.05 (-0.38%)

SAIC

SAIC

$83.40

-0.56 (-0.67%)

BMRN

BioMarin

$88.36

-0.64 (-0.72%)

JNJ

Johnson & Johnson

$112.56

-0.57 (-0.50%)

VRTX

Vertex

$86.90

-0.87 (-0.99%)

NVLS

Nivalis Therapeutics

$6.25

-0.03 (-0.48%)

X

U.S. Steel

$30.61

-1.56 (-4.85%)

  • 29

    Nov

  • 01

    Dec

  • 02

    Dec

  • 02

    Dec

  • 03

    Dec

  • 07

    Dec

  • 08

    Dec

  • 14

    Dec

  • 28

    Jan

  • 27

    Apr

WEN Wendy's
$12.94

-0.05 (-0.38%)

08/11/16
08/11/16
DOWNGRADE

On The Fly: Top five analyst downgrades
Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. Wendy's (WEN) downgraded to Buy from Conviction Buy at Goldman with analyst Karen Holthouse citing execution risk and the potential for additional fiscal 2016 same-store sales guidance reductions. 2. Bristol-Myers (BMY) downgraded to Hold from Buy at Berenberg. 3. Public Storage (PSA) downgraded to Neutral from Buy at BofA/Merrill with analyst Jeffery Spector citing valuation and increasing concessions in weaker markets. 4. Lam Research (LRCX) downgraded to Neutral from Buy at Nomura with analyst Romit Shah citing the extended timeline for its merger with KLA-Tencor (KLAC) after the Department of Justice requested more information. 5. Quorum Health (QHC) downgraded to Sell from Neutral at UBS with analyst A.J. Rice saying the company's earnings power is "much less than thought" after its second quarter results missed expectations. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
11/28/16
GSCO
11/28/16
DOWNGRADE
GSCO
Neutral
Wendy's downgraded to Neutral from Buy at Goldman
Goldman Sachs analyst Karen Holthouse downgraded Wendy's to Neutral citing valuation with the stock up 23% over the past month. The analyst views the current risk/reward as balanced and keeps a $12.50 price target for the shares.
11/25/16
ARGS
11/25/16
UPGRADE
Target $15
ARGS
Buy
Wendy's upgraded to Buy from Hold at Argus
Argus analyst John Staszak upgraded Wendy's to Buy with a $15 price target saying the company has revitalized its brand over the last three years by selling more than 800 company-owned restaurants. The sale of these restaurants has boasted free cash flow as franchisees are responsible for most capital expenditures and sale proceeds are providing capital for share buybacks and dividend increases, the analyst wrote. Staszak said by year end, franchisees will own 95% of all Wendy's restaurants and only 5% will be company-owned. The company and franchisees have remodeled 30% of restaurants, which are generating significantly greater revenue than older locations, Staszak said.
11/10/16
RHCO
11/10/16
NO CHANGE
RHCO
Wendy's gaining significant market share, says SunTrust
After Wendy's reported higher than expected Q3 EPS and same-store sales, SunTrust analyst Jake Bartlett says that the company "is taking significant market share" due to its traffic gains. The analyst keeps a $13 price target and a Buy rating on the shares.
SAIC SAIC
$83.40

-0.56 (-0.67%)

11/11/16
DRXL
11/11/16
UPGRADE
DRXL
Buy
SAIC upgraded to Buy from Hold at Drexel Hamilton
09/09/16
DRXL
09/09/16
DOWNGRADE
DRXL
Hold
SAIC downgraded to Hold from Buy at Drexel Hamilton
Drexel Hamilton analyst Michael French downgraded SAIC to Hold citing the recent strength in shares.
09/09/16
09/09/16
DOWNGRADE

On The Fly: Top five analyst downgrades
Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. JPMorgan (JPM) downgraded to Neutral from Outperform at Macquarie with analyst David Konrad citing valuation. 2. CarMax (KMX) downgraded to Neutral from Buy at Buckingham with analyst Glenn Chin citing valuation. 3. Eaton (ETN) and Ingersoll-Rand (IR) downgraded to Sector Weight from Overweight at KeyBanc with analyst Jeffrey Hammond citing his more cautious outlook for nonresidential construction. 4. Estee Lauder (EL) downgraded to Hold from Buy at Argus with analyst John Staszak saying it will be difficult for the company to achieve further market share gains, given increased competition, slowing growth in the premium beauty products space, and a "challenging" macro environment. 5. SAIC (SAIC) downgraded to Market Perform from Outperform at Cowen and to Hold from Buy at Drexel Hamilton. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
11/29/16
SBSH
11/29/16
DOWNGRADE
Target $86
SBSH
Neutral
SAIC downgraded to Neutral from Buy at Citi
Citi analyst Jonathan Raviv downgraded SAIC (SAIC) to Neutral citing the recent rally in the shares and some overhang from the pending contract transition. The analyst raised his price target for the stock to $86 from $79. Leidos (LDOS) remains Raviv's top pick in the space. He raised his price target for those shares to $60 from $51. He also raised his price target for Buy-rated CACI to $152 from $115.
BMRN BioMarin
$88.36

-0.64 (-0.72%)

11/29/16
LEHM
11/29/16
DOWNGRADE
Target $105
LEHM
Equal Weight
BioMarin downgraded to Equal Weight from Overweight at Barclays
Barclays analyst Geoff Meacham downgraded BioMarin to Equal Weight and lowered its price target to $105 from $125. The analyst said moderating growth and lack of 2017 catalysts provide only modest upside opportunity over the next 12 months.
11/09/16
RBCM
11/09/16
NO CHANGE
RBCM
Biotech stocks should be bought on post-election decline, says RBC Capital
RBC Capital recommends buying biotech stocks today on weakness. The firm notes that stocks usually rebound after they drop due to political events that don't affect their fundamentals, and it believes that the decline in biotech stocks today is in that category. The firm says that President-elect Trump probably won't focus on drug prices or Medicare reform. It adds that biotech companies should benefit from the fact that Congress will stay in GOP hands and the apparent failure of California's Proposition 61 initiative. The firm identifies Celgene (CELG), Biogen (BIIB), Vertex (VRTX), BioMarin (BMRN), and Prothena (PRTA) as its favorite names in the sector.
11/18/16
GABE
11/18/16
NO CHANGE
Target $99
GABE
Buy
Incyte, Regeneron among Gilead M&A options after latest setback, says Gabelli
Gabelli analyst Jing He noted Gilead's (GILD) "mixed" results from its Phase III trials evaluating momelotinib, which showed that the drug is not superior to Incyte's (INCY) Jakafi. Commenting on Gilead's potential path after momelotinib's "disappointing" results and several other pipeline setbacks this year, He suggested that Gilead could look to buy Incyte, which looks like "Regeneron lite," or simply buy Regeneron (REGN) itself. The analyst said Gilead could alternately target an orphan drug company such as Alexion (ALXN), Vertex (VRTX) or BioMarin (BMRN). She keeps a Buy rating and $99 per share private market value on Gilead shares, as she expects M&A to be a catalyst for the stock.
11/07/16
11/07/16
DOWNGRADE

On The Fly: Top five analyst downgrades
Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. BioMarin (BMRN) downgraded to Neutral from Overweight at Piper Jaffray with analyst Joshua Schimmer saying he sees a "number of under-appreciated" risks ahead. 2. Akorn (AKRX) downgraded to Underperform from Buy at BofA/Merrill and to Hold from Buy at WallachBeth. 3. GoPro (GPRO) downgraded to Underperform from Neutral at BofA/Merrill. 4. L Brands (LB) downgraded to Underperform from Hold at Jefferies with analyst Randal Konik citing rising competition and pricing competition. 5. Xerox (XRX) downgraded to Underweight from Equal Weight at Morgan Stanley with analyst Brian Essex saying both the BPO and DocTech businesses are facing secular pressures and said the Conduent spinco will add $2B of net incremental leverage and faces headwinds in both growth and pricing and will need to focus on margin expansion to drive shareholder value. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, cllick here.
JNJ Johnson & Johnson
$112.56

-0.57 (-0.50%)

11/29/16
LEHM
11/29/16
DOWNGRADE
Target $125
LEHM
Equal Weight
Johnson & Johnson downgraded to Equal Weight from Overweight at Barclays
Barclays analyst Geoff Meacham downgraded Johnson & Johnson to Equal Weight and lowered its price target to $125 from $130. The analyst said risk/reward is less compelling and said shares could become a source of funds due to Remicade biosimilar risk, slowing med tech utilization, reduced pipeline impact, and a move away from defensive names.
11/09/16
RBCM
11/09/16
NO CHANGE
RBCM
Johnson & Johnson should be bought on recent weakness, says RBC Capital
After meeting with J&J's VP, Investor Relations, RBC Capital analyst Glenn Novarro says that the company's Q3 pharma results indicate that the growth of its major drugs can more than offset any declines in Remicade sales next year. The analyst quotes J&J as saying that it has not been using price hikes to increase its sales, and he thinks that the company's diverse business model will allow it to avoid being hurt by any regulatory pressures. He is upbeat on the company's efforts to increase its margins and notes that its medical device results have improved. Novarro keeps a $133 price target and an Outperform rating on the shares.
11/28/16
WELS
11/28/16
NO CHANGE
WELS
Actelion could be acquired for $215 per share, says Wells Fargo
After Johnson & Johnson (JNJ) said that it's in preliminary talks about a deal with Actelion (ALIOF), Wells Fargo estimates that J&J could buy Actelion for $215 per share. The firm thinks that other bidders could emerge for Actelion. It estimates that the deal could be accretive to J&J's EPS by about 5%. Wells keeps an Outperform rating on J&J.
10/19/16
UBSW
10/19/16
NO CHANGE
Target $144
UBSW
Buy
Johnson & Johnson has potential upside from expanding pipeline, says UBS
UBS analyst Matt Miksic noted Johnson & Johnson delivered a solid quarter and said he believes there is upside to his Buy thesis. The analyst cited the company's expanding pipeline, capital allocation strategy, and contracting across its broad portfolio and patient assistance programs is expected to help mitigate pressure from biosimilar competition. Miksic reiterated his Buy rating and raised his price target to $144 from $137 on Johnson & Johnson shares.
VRTX Vertex
$86.90

-0.87 (-0.99%)

11/29/16
LEHM
11/29/16
DOWNGRADE
Target $90
LEHM
Equal Weight
Vertex downgraded to Equal Weight from Overweight at Barclays
Barclays analyst Geoff Meacham downgraded Vertex to Equal Weight and lowered its price target to $90 from $100. Meacham is worried about high expectations and said VX-661 data expected in 1H 2017 is largely incremental and sees a lot of uncertainty for the triple combo.
11/17/16
JANY
11/17/16
INITIATION
JANY
Neutral
Vertex initiated with a Neutral at Janney Capital
11/18/16
JANY
11/18/16
INITIATION
Target $98
JANY
Neutral
Vertex initiated with a Neutral at Janney Capital
Janney Capital analyst Debjit Chattopadhyay initiated Vertex with a Neutral and a $98 price target citing valuation premium.
NVLS Nivalis Therapeutics
$6.25

-0.03 (-0.48%)

11/29/16
COWN
11/29/16
DOWNGRADE
COWN
Market Perform
Nivalis Therapeutics downgraded to Market Perform at Cowen
As reported previously, Cowen analyst Phil Nadeau downgraded Nivalis Therapeutics to Market Perform from Outperform. The analyst said its proof-of-concept Phase 2 trial for cystic fibrosis demonstrated no benefits for lung function or sweat chloride, two established measures of activity. The drug was the company's primary asset, Nadeau noted.
11/29/16
STFL
11/29/16
DOWNGRADE
STFL
Hold
Nivalis Therapeutics downgraded on lack of drug efficacy at Stifel
As noted earlier, Stifel downgraded Nivalis to Hold from Buy. Analyst Thomas Shrader downgraded the stock after the company's cavosonstat for CF did not show meaningful efficacy in a Phase II trial. Target to $3.25 from $16.
11/29/16
11/29/16
DOWNGRADE
Target $3

Neutral
Nivalis Therapeutics downgraded to Neutral at Baird
As previously reported, Baird analyst Brian Skorney downgraded Nivalis Therapeutics to Neutral from Outperform following the clinical trial failure of its flagship proof-of-concept study of its drug for cystic fibrosis. Skorney lowered his price target to $3 from $29 on Nivalis Therapeutics shares. Nivalis shares have also been downgraded by at least three other firms this morning.
11/29/16
BARD
11/29/16
DOWNGRADE
BARD
Neutral
Nivalis Therapeutics downgraded to Neutral from Outperform at Baird
X U.S. Steel
$30.61

-1.56 (-4.85%)

11/29/16
ARGS
11/29/16
DOWNGRADE
ARGS
Hold
U.S. Steel downgraded to Hold from Buy at Argus
11/21/16
11/21/16
DOWNGRADE

Neutral
Follow-up: U.S. Steel downgraded on valuation, slowing auto growth at Rosenblatt
As previously reported, Rosenblatt downgraded U.S. Steel to Neutral from Buy. Analyst Chris Olin said shares appear fairly valued given recent share strength and reduced demand visibility and decelerating automotive growth.
11/21/16
RSBL
11/21/16
DOWNGRADE
RSBL
Neutral
U.S. Steel downgraded to Neutral from Buy at Rosenblatt
11/14/16
11/14/16
UPGRADE

On The Fly: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. Lockheed Martin (LMT) upgraded to Buy from Hold at Stifel with analyst Joseph DeNardi saying he is pleased with the company's comments regarding its 2018 free cash flow outlook, and he thinks that it could benefit from increased defense spending in the wake of the election results. 2. Philip Morris (PM) upgraded to Buy from Outperform at CLSA with analyst Michael Levy citing the recent pullback for his rating change and said he sees the company adding to its buyback. 3. Citi (C) upgraded to Overweight from Equal Weight at Morgan Stanley with analysts led by Betsy Graseck saying the Republican sweep is positive for all financial stocks due to increased growth, higher rates, lower taxes, and less regulation. 4. U.S. Steel (X) and AK Steel (AKS) upgraded to Overweight from Equal Weight at Morgan Stanley. 5. L Brands (LB), Kohl's (KSS), and Chico's(CHS) were upgraded to Buy from Neutral at Citi, while Chico's was also upgraded to Outperform from Peer Perform at Wolfe Research. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.

TODAY'S FREE FLY STORIES

FMSA

Fairmount Santrol

$9.27

-0.08 (-0.86%)

17:06
12/07/16
12/07
17:06
12/07/16
17:06
Hot Stocks
Breaking Hot Stocks news story on Fairmount Santrol »

Point72 Asset reports…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    Dec

COVS

Covisint

$2.30

0.1 (4.55%)

17:01
12/07/16
12/07
17:01
12/07/16
17:01
Hot Stocks
Covisint signs agreements with SAIC General Motors, NextEV »

Covisint Corporation…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AMZN

Amazon.com

$770.19

5.47 (0.72%)

17:01
12/07/16
12/07
17:01
12/07/16
17:01
Hot Stocks
Amazon launches menswear brand 'Buttoned Down' »

Amazon announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AMC

AMC Entertainment

$32.65

-1.15 (-3.40%)

16:50
12/07/16
12/07
16:50
12/07/16
16:50
Hot Stocks
Breaking Hot Stocks news story on AMC Entertainment »

Monterey Capital III…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MCFT

MCBC Holdings

$14.18

0.23 (1.65%)

16:43
12/07/16
12/07
16:43
12/07/16
16:43
Syndicate
MCBC Holdings files to sell 1M shares of common stock for holders »

B. Riley and Co. is…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ECC

Eagle Point Credit

$17.97

-0.03 (-0.17%)

16:42
12/07/16
12/07
16:42
12/07/16
16:42
Syndicate
Eagle Point Credit files to sell 1.15M shares of common stock »

Keefe, Bruyette &…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

16:39
12/07/16
12/07
16:39
12/07/16
16:39
General news
Moody's changes outlook on Italy to negative from stable »

Moody's Investors…

DNB

Dun & Bradstreet

$123.83

2.42 (1.99%)

16:39
12/07/16
12/07
16:39
12/07/16
16:39
Hot Stocks
Dun & Bradstreet appoints CEO Robert Carrigan as chairman »

Dun & Bradstreet…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MIND

Mitcham Industries

$3.73

0.04 (1.08%)

16:35
12/07/16
12/07
16:35
12/07/16
16:35
Earnings
Mitcham Industries reports Q3 EPS (62c), consensus (43c) »

Reports Q3 revenue $8.1M,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CPG

Crescent Point Energy

$13.30

0.09 (0.68%)

16:35
12/07/16
12/07
16:35
12/07/16
16:35
Hot Stocks
Crescent Point Energy announces $1.45B CapEx budget for 2017 »

Crescent Point Energy is…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GLW

Corning

$24.58

0.59 (2.46%)

16:34
12/07/16
12/07
16:34
12/07/16
16:34
Hot Stocks
Corning announces $4B share repurchase program »

Corning announced that…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

WTT

Wireless Telecom Group Inc

$1.58

0.01 (0.64%)

16:33
12/07/16
12/07
16:33
12/07/16
16:33
Hot Stocks
Wireless Telecom Group Inc appoints Michael Kandell as CFO »

Wireless Telecom Group,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ARGS

Argos Therapeutics

$4.85

0.1 (2.11%)

16:33
12/07/16
12/07
16:33
12/07/16
16:33
Hot Stocks
Argos announces rocapuldencel-T as generic name for AGS-003 »

Argos Therapeutics…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    Dec

WWE

WWE

$19.43

0.48 (2.53%)

16:33
12/07/16
12/07
16:33
12/07/16
16:33
Hot Stocks
WWE co-founder says appointed by Trump to lead Small Business Administration »

Linda McMahon, WWE…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

WPC

W.P. Carey

$59.52

1.08 (1.85%)

16:31
12/07/16
12/07
16:31
12/07/16
16:31
Hot Stocks
W.P. Carey raises quarterly dividend to 99c per share »

W.P. Carey reported that…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CM

CIBC

$83.70

1.28 (1.55%)

, PVTB

PrivateBancorp

$52.39

0.25 (0.48%)

16:30
12/07/16
12/07
16:30
12/07/16
16:30
Conference/Events
PrivateBancorp to host special shareholder meeting »

Special Shareholder…

CM

CIBC

$83.70

1.28 (1.55%)

PVTB

PrivateBancorp

$52.39

0.25 (0.48%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 08

    Dec

16:30
12/07/16
12/07
16:30
12/07/16
16:30
Options
Preliminary option volume of 21.5M today »

Preliminary option volume…

CMTL

Comtech

$12.75

0.77 (6.43%)

16:26
12/07/16
12/07
16:26
12/07/16
16:26
Hot Stocks
Comtech declares 10c quarterly dividend, sees FY17 quarterly dividends unchanged »

Comtech…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 08

    Dec

  • 08

    Dec

SKLN

Skyline Medical

16:26
12/07/16
12/07
16:26
12/07/16
16:26
Hot Stocks
Breaking Hot Stocks news story on Skyline Medical »

Nations Advisory Partners…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SKLN

Skyline Medical

16:25
12/07/16
12/07
16:25
12/07/16
16:25
Hot Stocks
Breaking Hot Stocks news story on Skyline Medical »

River North Equity…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SKLN

Skyline Medical

16:25
12/07/16
12/07
16:25
12/07/16
16:25
Hot Stocks
Breaking Hot Stocks news story on Skyline Medical »

Kodiak Capital reports…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ZEN

Zendesk

$21.15

-0.02 (-0.09%)

16:25
12/07/16
12/07
16:25
12/07/16
16:25
Conference/Events
William Blair software/SaaS analyst holds a tech roundtable dinner meeting »

Software/SaaS Analyst…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    Dec

  • 08

    Dec

TYL

Tyler Technologies

$147.73

1.54 (1.05%)

16:24
12/07/16
12/07
16:24
12/07/16
16:24
Hot Stocks
Tyler Technologies rejects media reports of issues with Odyssey product »

Tyler Technologies issued…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 13

    Dec

  • 14

    Dec

HRB

H&R Block

$23.34

0.65 (2.86%)

16:24
12/07/16
12/07
16:24
12/07/16
16:24
Earnings
H&R Block reports Q2 continuing ops EPS (67c), consensus (68c) »

Reports Q2 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    Dec

TSN

Tyson Foods

$58.82

1.43 (2.49%)

16:24
12/07/16
12/07
16:24
12/07/16
16:24
Hot Stocks
Tyson incoming CEO Tom Hayes sees growth in retail, foodservice businesses »

Tyson Foods president and…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    Dec

  • 08

    Dec

  • 09

    Dec

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.